What is B. Riley’s Forecast for OBIO Q1 Earnings?

Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) – Investment analysts at B. Riley issued their Q1 2026 earnings estimates for shares of Orchestra BioMed in a note issued to investors on Thursday, April 3rd. B. Riley analyst A. Schock expects that the company will post earnings per share of ($0.54) for the quarter. B. Riley currently has a “Strong-Buy” rating on the stock. The consensus estimate for Orchestra BioMed’s current full-year earnings is ($1.66) per share. B. Riley also issued estimates for Orchestra BioMed’s Q2 2026 earnings at ($0.43) EPS, Q3 2026 earnings at ($0.42) EPS, Q4 2026 earnings at ($0.38) EPS and FY2026 earnings at ($1.76) EPS.

Several other research firms have also recently issued reports on OBIO. Chardan Capital reissued a “buy” rating and issued a $20.00 target price on shares of Orchestra BioMed in a report on Tuesday, April 1st. HC Wainwright decreased their price target on shares of Orchestra BioMed from $14.00 to $12.00 and set a “buy” rating on the stock in a research note on Friday. BTIG Research initiated coverage on Orchestra BioMed in a research report on Thursday, March 20th. They set a “buy” rating and a $12.00 price objective for the company. Finally, Barclays began coverage on Orchestra BioMed in a research report on Thursday, January 2nd. They issued an “overweight” rating and a $16.00 target price on the stock. Four research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Orchestra BioMed has an average rating of “Buy” and an average price target of $15.00.

Orchestra BioMed Trading Up 2.5 %

NASDAQ OBIO opened at $2.83 on Monday. Orchestra BioMed has a 12 month low of $2.49 and a 12 month high of $8.87. The stock has a market cap of $107.58 million, a PE ratio of -1.76 and a beta of 0.62. The stock’s 50 day moving average is $4.65 and its 200 day moving average is $5.09.

Orchestra BioMed (NASDAQ:OBIO) last announced its quarterly earnings data on Monday, March 31st. The company reported ($0.43) EPS for the quarter, meeting the consensus estimate of ($0.43). Orchestra BioMed had a negative return on equity of 107.04% and a negative net margin of 2,179.33%. The business had revenue of $0.25 million for the quarter, compared to the consensus estimate of $0.79 million.

Hedge Funds Weigh In On Orchestra BioMed

Several institutional investors have recently bought and sold shares of the business. Millennium Management LLC bought a new stake in shares of Orchestra BioMed in the 4th quarter worth about $86,000. Bank of America Corp DE grew its position in Orchestra BioMed by 42.0% in the fourth quarter. Bank of America Corp DE now owns 23,780 shares of the company’s stock worth $95,000 after acquiring an additional 7,036 shares in the last quarter. Boxer Capital Management LLC bought a new stake in Orchestra BioMed during the fourth quarter worth approximately $953,000. Northern Trust Corp increased its stake in Orchestra BioMed by 2.5% during the fourth quarter. Northern Trust Corp now owns 236,761 shares of the company’s stock worth $947,000 after acquiring an additional 5,725 shares during the last quarter. Finally, The Manufacturers Life Insurance Company raised its position in Orchestra BioMed by 11.1% during the fourth quarter. The Manufacturers Life Insurance Company now owns 37,009 shares of the company’s stock valued at $148,000 after purchasing an additional 3,704 shares during the period. Institutional investors own 53.55% of the company’s stock.

About Orchestra BioMed

Orchestra BioMed Holdings, Inc operates as a biomedical innovation company. The company’s flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease.